Dapagliflozin in Patients with Chronic Kidney Disease. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC for the DAPA-CKD Trial Committees and Investigators. I currently provide strategic research leadership in my roles as Co-Medical Director of the National Institute of Health Research (NIHR) North Thames Clinical Research Network and NIHR National Specialty Lead for Renal Disorders.
At a local level I manage the Clinical Research Team in the Department of Renal Medicine at The Royal Free Hospital and thereby oversee participation of our patients in clinical research activities. I have been involved in the academic leadership of several trials assessing therapies including statins, calcimimetics, hypoxia-inducible factor (HIF) stabilizers, intravenous iron and sodium glucose co-transporter 2 (SGLT2) inhibitors. My research is focussed on the evaluation of new therapies for CKD patients through the conduct of randomised controlled trials. Early therapeutic interventions that slow progression of chronic kidney disease (CKD) and reduce the impact of its complications should improve outcomes for these individuals. People with chronic kidney disease have a shortened life expectancy, despite treatment with dialysis and kidney transplantation.